What the Evidence Actually Shows: Flotation-REST for Chronic Pain
- Rebecca Nolan Harris, PhD
- Jul 10
- 4 min read
A clinical summary for healthcare providers
Chronic pain touches roughly a quarter of American adults, and a meaningful share of them live with pain severe enough to limit daily function. With opioid-related harms remaining a major public health concern, clinicians and patients alike are looking harder at non-pharmacological options. A newly published scoping review in the Journal of Pain Research takes a close look at one such option: flotation-REST (Restricted Environmental Stimulation Therapy) — the practice of floating supine in a body-temperature, Epsom-salt-saturated tank that minimizes light, sound, and gravitational input.
The review, led by Sam J. Stuart and colleagues at Indiana University School of Medicine and the VA Center for Health Information and Communication, is the first to focus specifically on flotation-REST's effects on chronic pain and its common comorbidities, rather than on stress or performance outcomes more broadly.
What They Did
The authors searched Ovid MEDLINE, Cochrane Library, Embase, and PsycINFO from inception through January 2025, screening over 9,000 records. After full-text review, eight studies met inclusion criteria: six randomized controlled trials and two single-arm pre/post studies, representing a combined 401 participants. Because intervention protocols, control conditions, and outcome measures varied so widely across studies, the authors opted for a qualitative scoping review rather than a meta-analysis.
Study populations generally fell between 30 and 50 years of age, with chronic neck, back, or stress-related muscular pain as the most common presenting conditions. Protocols ranged considerably — anywhere from 5 to 33 sessions, delivered over 20 days to 35 weeks, with individual sessions typically lasting 45 to 90 minutes.
What They Found Regarding Flotation-REST for Chronic Pain
Pain. Across nearly all included studies, flotation-REST was associated with reduced pain frequency and intensity, fewer distinct pain areas, and improved pain tolerance and detection thresholds. The exception was the most methodologically rigorous trial in the set — a 2021 study by Loose and colleagues that used an active control condition designed to mimic the sensory-restriction experience. In that trial, both the flotation and control groups improved similarly in the short term, and neither group maintained significant pain benefit at six months.
Anxiety and depression. Every study that measured anxiety reported improvement, with one showing benefits sustained at four months post-treatment. Depression outcomes were similarly favorable in most studies, though the Loose trial again found no significant depression benefit.
Sleep and stress. Findings were mixed. Some studies found improved sleep latency without corresponding gains in duration or quality; others found sleep quality improvements that persisted for months. Stress reduction was one of the more consistent findings, appearing in most studies and in some cases persisting at four-month follow-up.
Mood and relaxation. Optimism scores rose in multiple studies, with effects maintained at four months in at least one. Findings on positive/negative affect were inconsistent across studies.
Physiology and biomarkers. This is where the evidence gets notably weaker. Diastolic blood pressure decreased in several studies, but systolic pressure and heart rate showed little consistent change. Biomarker findings were frankly contradictory: one study found reduced levels of MHPG (a norepinephrine metabolite) post-treatment, but no significant change in beta-endorphins — and beta-endorphin levels were, paradoxically, higher in the control group. Prolactin rose immediately post-treatment in one study but returned to baseline within four months.
Safety. No adverse events were reported in any of the eight studies, during treatment, immediately after, or at follow-up.
The Caveats That Matter Clinically
The authors are candid about the limitations, and providers should weigh them carefully before making claims to patients:
Most outcomes relied on self-report, which is vulnerable to expectancy effects — particularly in studies where participants were already familiar with the flotation facility or staff.
Several studies lacked randomization or any control group at all.
No two studies used the same session count, duration, or environmental parameters (tank size, lighting, sound insulation), making it impossible to say what an "optimal" protocol looks like.
Follow-up beyond 24 hours was rare, so durability of benefit — especially for pain specifically — remains an open question.
The one trial designed with a genuinely active control (Loose et al., 2021) found that a large share of the benefit may be attributable to placebo, expectancy, or general relaxation response rather than anything unique to flotation.
Bottom Line for Providers
The consistency of pain, anxiety, and stress reduction across a heterogeneous set of studies is encouraging, and the safety profile is clean — no adverse events across 401 participants. That said, the physiological and biomarker data don't yet tell a coherent mechanistic story, and the field's best-controlled trial raises real questions about how much of the effect is specific to sensory restriction versus general relaxation and placebo response.
Flotation-REST is reasonable to discuss with patients as a low-risk complementary option alongside — not in place of — established chronic pain management, with the caveat that long-term efficacy data are still thin. The authors call for standardized protocols, larger samples, longer follow-up, and mechanistic work (EEG, fMRI, additional neuroendocrine markers) before flotation-REST can be considered a well-established evidence-based intervention.
Source: Stuart SJ, Achury LK, Kline M, Bair MJ. A Scoping Review of Flotation-REST (Restricted Environmental Stimulation Therapy) for Chronic Pain and Associated Comorbidities. Journal of Pain Research. 2026;19:565238. doi:10.2147/JPR.S565238. Published under CC BY-NC 4.0.
Comments